A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
This is a continuation U.S. patent application Ser. No. 10/256,993 filed Sep. 27, 2002 now U.S Pat. No. 6,620,814 which is a continuation of U.S. patent application Ser. No. 09/925,871 filed Aug. 9, 2001 now U.S. Pat. No. 6,525,057 which is a continuation of U.S. patent application Ser. No. 09/321,522 filed on May 27, 1999 now U.S. Pat. No. 6,303,607 which claims priority to U.S. patent application serial No. 60/099,804 filed on Sep. 10, 1998, the specifications of each of which are incorporated herein by reference.
